LAS VEGAS, June 25, 2020 /PRNewswire/ -- JanOne Inc.
(NASDAQ: JAN), a company focused on bringing treatments to market
for conditions that cause severe pain and drugs with non-addictive
pain relieving properties, continues to build a world-class team of
biopharma experts with the addition of Douglas Flanagan, PhD as the company's chief
formulation advisor. Dr. Flanagan will work directly with CoreRX,
JanOne's manufacturing partner to ensure the integrity of TV1001SR,
the company's clinical candidate for treating Peripheral Artery
Disease (PAD) expected soon to enter phase 2 trials. He will
also play an integral role for the potential identification and
advancement of other clinical candidates to treat pain as the
company hopes to broaden its pipeline in the near future.
According to Tony Isaac, JanOne's
chief executive officer, "We are confident that Dr. Flanagan's
extensive accomplishments as a researcher, chemist and formulation
advisor to some of the world's leading biopharma companies will
ensure proper formulation of our clinical candidates. We welcome
his expertise and look forward to his contribution to our future
success."
Dr. Flanagan brings over 40 years of scientific, pharmaceutical
formulation and clinical experience and has published over 90 peer
reviewed articles and delivered over 150 presentations, talks and
lectures around the world. He has lent his formulation expertise to
over 50 pharmaceutical companies and medical organizations
including Abbott Laboratories, Pfizer Animal Health (spun off as
Zoetis), Bristol Myers Squibb, the World Health Organization and
the Federal Drug Administration(FDA) to name a few. In addition to
serving as an expert witness to successfully litigate various
pharmaceutical patents, Dr. Flanagan also holds various formulation
patents, including pharmaceutical formulations of nitrite, a key
component of TV1001SR. Dr. Flanagan was appointed as Emeritus
Professor at the University of Iowa
College of Pharmacy where he served as a faculty member for 34
years.
Dr Flanagan commented, "I am pleased to advise the team at
JanOne. I hope to help accelerate treatments for diseases that
cause severe pain such as PAD. I also share in the company's
ultimate mission to reduce the need for opioid prescriptions by
bringing to market non-addictive pain relieving formulations."
About JanOne
JanOne is a unique NASDAQ-listed company that is focused on
bringing medications to market to treat diseases that cause severe
pain in an effort to reduce the need for prescriptions opioids
often used to treat disease associated pain. The company is also
exploring solutions for non-addictive pain medications. The lead
candidate is for treating peripheral artery disease (PAD), a
condition that affects over 8.5 million Americans, with plans
currently underway for phase 2b
trials. JanOne is currently dedicated to funding resources toward
innovation, technology, and education for PAD and neuropathic pain.
The company continues to operate its legacy businesses, ARCA
Recycling and GeoTraq, under their current brand names. ARCA
Recycling provides turnkey recycling and replacement services for
utilities and other sponsors of energy efficiency programs. GeoTraq
engages in the development, design and, ultimately, the company
expects, sale of Mobile IoT modules. Please visit www.janone.com
for additional information.
Forward-Looking Statements
This press release contains statements that are forward-looking
statements as defined within the Private Securities Litigation
Reform Act of 1995, including, but not limited to, statements
relating to the company's expectation that TV1001SR will soon enter
phase 2 trials, the identification of other potential candidates to
treat pain, and other statements including words such as
"continue", "expect", "intend", "will", "hope" "should", "would",
"may", "potential" and other similar expressions. Such statements
reflect our current views with respect to future events and are
subject to risks and uncertainties and are necessarily based upon a
number of estimates and assumptions that, while considered
reasonable by us, are inherently subject to significant business,
economic, competitive, political and social uncertainties, and
contingencies. Many factors could cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements described in this press
release. Such factors could include, among others, those detailed
in the Company's periodic reports filed with the Securities and
Exchange Commission (the "SEC").
Should one or more of these risks or uncertainties materialize,
or should the assumptions set out in the section entitled "Risk
Factors" in our filings with the SEC underlying those
forward-looking statements prove incorrect, actual results may vary
materially from those described herein. These forward-looking
statements are made as of the date of this press release and we do
not intend, and do not assume any obligation, to update these
forward-looking statements, except as required by law. We cannot
assure you that such statements will prove to be accurate as actual
results and future events could differ materially from those
anticipated in such statements. Investors are cautioned that
forward-looking statements are not guarantees of future performance
and accordingly investors are cautioned not to put undue reliance
on forward-looking statements due to the inherent uncertainty
therein.
Media contact:
Mark Rosenberg |
mark@trueparallel.com | 919-412-7378
View original content to download
multimedia:http://www.prnewswire.com/news-releases/janone-taps-distinguished-chemist-dr-doug-flanagan-as-chief-formulation-advisor-301083950.html
SOURCE JanOne